Updates on Availability of BCG

By Policy and Advocacy Brief posted 01-17-2019 13:45


As part of our ongoing efforts to monitor drug supply issues, the AUA recently reached out to Merck regarding member concerns about recent changes in availability for bacillus Calmette-Guerin (BCG). Due to increased need globally for BCG and anticipated supply constraints, Merck has announced a shift in the distribution model for its TICE® BCG product and is in the process of communicating changes with providers and practices.

Learn more from the FDA.

The AUA will continue to provide updates as information becomes available. Members with questions are urged to contact the Merck National Service Center at 1-800-672-6372.